Switching to weekly semaglutide may be beneficial when other GLP-1 RAs are unable to achieve sufficient weight reduction, given that further management of obesity is recommended to achieve better cardiovascular and renal outcomes (14). This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.